Novo Nordisk (NVO) has launched its recently approved pill version of the blockbuster weight loss treatment, Wegovy, for cash-paying U.S. customers at $149 per month, weeks after its FDA approval in December.
According to a company-maintained website, the oral GLP-1 product for a 30-day supply will cost $149 for 1.5 mg and 4 mg doses, while two higher doses of 9 mg and 25 mg will be available at $299 per month. The offer for 4 mg will last until Apr. 15 before the price rises to $199 per month.
The semaglutide version is administered once daily at 1.5 mg for the first month and 4 mg and 9 mg for the second and third months, respectively, before the maintenance dosing gets underway at 25 mg per day.
In December, the FDA approved the Wegovy pill for weight management and to reduce the risk of major adverse cardiovascular events such as stroke, giving the Danish drugmaker the first-mover advantage in the market for oral weight loss drugs.
Eli Lilly (LLY), which is awaiting a potential FDA approval of its weight loss pill orforglipron in early 2026, is planning to launch its small molecule product at $149 per month for the lowest starting dose.